On June 30, Kelun-Biotech Biopharmaceutical rose 4.04% in regular trading, trading at 440.8 HKD/share, with turnover of 38.58 million HKD.

The stock continues to benefit from sustained catalysts following the disclosure of Phase III OptiTROP-Lung05 study results at the ASCO annual meeting. Multiple institutions have issued bullish calls: Nomura raised its target price to 544.42 HKD maintaining a Buy rating based on improved sales outlook, Industrial Securities initiated coverage with an Overweight rating, while CITIC Construction Investment and China Post Securities both maintained Buy ratings.

The OptiTROP-Lung05 study demonstrated that sac-TMT combined with pembrolizumab significantly extended progression-free survival in first-line PD-L1 positive NSCLC patients, with a PFS hazard ratio of 0.35 and 12-month PFS rate of 62.4% versus 29.0% for pembrolizumab monotherapy. Additionally, partner Windward Bio completed first patient dosing in a Phase II study of ultra-long-acting anti-TSLP antibody SKB378/WIN378 for COPD treatment, further advancing the pipeline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)